<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="Data Sources: Published literatures in Chinese and English on hepatoprotective" exact="treatment" post="strategies for chronic hepatitis B and liver fibrosis were"/>
 <result pre="Silibinin Acetylcysteine 1. Context At present, Hepatitis B Virus (HBV)" exact="infection" post="is an important public health problem worldwide. Hepatitis B"/>
 <result pre="liver dysfunction (3-5). Early cirrhosis may be reversible. Therefore, prompt" exact="diagnosis" post="and intervention are critical in limiting disease progression (6)."/>
 <result pre="4.1. Inclusion and Exclusion Criteria 4.1.1. Inclusion Criteria Hepatitis B" exact="infection" post="or liver fibrosis; chronic hepatitis B was diagnosed if"/>
 <result pre="Results 6.1. Retrieval Results Initially, 245 papers were retrieved by" exact="screening" post="the title, abstract, and inclusion and exclusion criteria. Finally,"/>
 <result pre="et al. (20) 58 57 NAC (8 g/d) + basic" exact="treatment" post="Basic treatment (Potassium magnesium aspartate 2 g/d + promote"/>
 <result pre="(20) 58 57 NAC (8 g/d) + basic treatment Basic" exact="treatment" post="(Potassium magnesium aspartate 2 g/d + promote the liver"/>
 <result pre="et al. (21) 20 20 NAC (8 g/d) + basic" exact="treatment" post="Basic treatment (Vitamin K 10 mg/d + promote the"/>
 <result pre="(21) 20 20 NAC (8 g/d) + basic treatment Basic" exact="treatment" post="(Vitamin K 10 mg/d + promote the liver cell"/>
 <result pre="et al. (22) 18 20 NAC (1.2 g/d) + basic" exact="treatment" post="Basic treatment (lamivudine + pegylated interferon + adefovir) 45"/>
 <result pre="(22) 18 20 NAC (1.2 g/d) + basic treatment Basic" exact="treatment" post="(lamivudine + pegylated interferon + adefovir) 45 d ALT,"/>
 <result pre="Wu et al. (23) 72 72 NAC(8 g/d) + basic" exact="treatment" post="Basic treatment (Vitamin K 10 mg/d + promote the"/>
 <result pre="al. (23) 72 72 NAC(8 g/d) + basic treatment Basic" exact="treatment" post="(Vitamin K 10 mg/d + promote the liver cell"/>
 <result pre="al. (36) 45 44 Silibinin (0.315 g/d) + protect liver" exact="treatment" post="+ Lamivudine (0.1 g/d) Protect liver treatment (energy mixture,"/>
 <result pre="+ protect liver treatment + Lamivudine (0.1 g/d) Protect liver" exact="treatment" post="(energy mixture, inosine, salvia miltiorrhiza, promoting liver cell growth"/>
 <result pre="of a hepatoprotective drug in combination with an antiviral agent" exact="treatment" post="of chronic hepatitis B. The test and control groups"/>
 <result pre="ALP and TBIL Levels In patients with chronic hepatitis B" exact="infection" post="treated with combination hepatoprotective and antiviral drug vs. antiviral"/>
 <result pre="including ALT and TBIL. In these trials, the control and" exact="treatment" post="groups included 144 and 140 subjects, respectively; since there"/>
 <result pre="Reduced Amounts of ALT In patients with chronic hepatitis B" exact="infection" post="treated with hepatoprotective drugs vs. placebo. Data are presented"/>
 <result pre="Forest Plots for Effects In patients with chronic hepatitis B" exact="infection" post="treated with the combination of two liver protective drugs"/>
 <result pre="of ALT and TBIL In patients with chronic hepatitis B" exact="infection" post="treated with two vs. one hepatoprotective agent. Data are"/>
 <result pre="7. Discussion The current model is expected to maximize long-term" exact="treatment" post="of severe liver disease caused by HBV infection to"/>
 <result pre="maximize long-term treatment of severe liver disease caused by HBV" exact="infection" post="to suppress the virus, improve inflammation and necrosis, and"/>
 <result pre="results of the current study showed that after a certain" exact="treatment" post="course of a combined hepatoprotective and antiviral drugs, liver"/>
 <result pre="clinical efficiency of adenosine combine with ursodeoxycholic acid in the" exact="treatment" post="of chronic hepatitis B with severe jaundice.Chin Hosp Pharm"/>
 <result pre="randomized, and controlled study.BMC Surg.2013133810.1186/1471-2482-13-3824053627 11BobergKMWisloffTKjollesdalKSStovringHKristiansenISCost and health consequences of" exact="treatment" post="of primary biliary cirrhosis with ursodeoxycholic acid.Aliment Pharmacol Ther.201338779480310.1111/apt.1243523915021"/>
 <result pre="biliary cirrhosis with ursodeoxycholic acid.Aliment Pharmacol Ther.201338779480310.1111/apt.1243523915021 12TkaczBDworniakD[Sylimarol in the" exact="treatment" post="of acute viral hepatitis].Wiad Lek.198336861366353775 13WeiFLiuSKLiuXYLiZJLiBZhouYLet al.Meta-analysis: silymarin and"/>
 <result pre="Lek.198336861366353775 13WeiFLiuSKLiuXYLiZJLiBZhouYLet al.Meta-analysis: silymarin and its combination therapy for the" exact="treatment" post="of chronic hepatitis B.Eur J Clin Microbiol Infect Dis.20133256576910.1007/s10096-012-1789-123247631"/>
 <result pre="and silibinin purification.Lishizhen Med Materia Med Res.20122336556 15FeherJLengyelG[Silymarin in the" exact="treatment" post="of chronic liver diseases: past and future].Orv Hetil.2008149512413810.1556/OH.2008.2851919073452 16HofferEBaumYTabakATaitelmanUN-acetylcysteine"/>
 <result pre="hepatotoxicity: An update.Curr Gastroenterol Rep.19991142910980926 19WangNShiXFGuoSHZhangDZRenH[A clinical study of N-acetylcysteine" exact="treatment" post="in chronic hepatitis B patients].Zhonghua Gan Zang Bing Za"/>
 <result pre="efficiency of adenosine methionine combined with ursodeoxycholic acid in the" exact="treatment" post="of chronic hepatitis B with severe jaundice.Chinese J Hos"/>
 <result pre="efficacy of ursodeoxycholic acid and fuzheng huayu capsule in the" exact="treatment" post="of primary biliary cirrhosis].Zhongguo Zhong Xi Yi Jie He"/>
</results>
